Predictions
Biogen Inc.
Start price
Target price
Perf. (%)
€205.20
12.05.24
12.05.24
€207.00
12.05.25
12.05.25
3.85%
06.06.24
06.06.24
Good rating
Standard Investments for future growth
Innovative
Differentiated customer and product portfolio
Biogen Inc.
Start price
Target price
Perf. (%)
€205.20
12.05.24
12.05.24
€207.00
12.05.25
12.05.25
3.85%
06.06.24
06.06.24
Good rating
Standard Investments for future growth
Innovative
Differentiated customer and product portfolio
Biogen Inc.
Start price
Target price
Perf. (%)
€205.20
12.05.24
12.05.24
€207.00
12.05.25
12.05.25
3.85%
06.06.24
06.06.24
Good rating
Standard Investments for future growth
Innovative
Differentiated customer and product portfolio
Biogen Inc.
Start price
Target price
Perf. (%)
€194.35
27.04.24
27.04.24
€200.00
27.04.25
27.04.25
5.58%
12.05.24
12.05.24
Good rating
Standard Investments for future growth
Innovative
Differentiated customer and product portfolio
Biogen Inc.
Start price
Target price
Perf. (%)
€194.35
27.04.24
27.04.24
€200.00
27.04.25
27.04.25
5.58%
12.05.24
12.05.24
Good rating
Standard Investments for future growth
Innovative
Differentiated customer and product portfolio
Biogen Inc.
Start price
Target price
Perf. (%)
€194.35
27.04.24
27.04.24
€200.00
27.04.25
27.04.25
5.58%
12.05.24
12.05.24
Good rating
Standard Investments for future growth
Innovative
Differentiated customer and product portfolio
Bristol-Myers Squibb
Start price
Target price
Perf. (%)
€39.55
02.02.24
02.02.24
-
-
03.02.24
03.02.24
Could be worthwhile Investment >10% per year
Bristol-Myers Squibb
Start price
Target price
Perf. (%)
€47.60
05.01.24
05.01.24
-
05.01.25
05.01.25
0.63%
05.03.24
05.03.24
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
High dividend yield expected
Good rating
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€75.96
02.01.24
02.01.24
€80.00
02.02.24
02.02.24
-6.29%
22.01.24
22.01.24
Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€75.96
02.01.24
02.01.24
€80.00
02.02.24
02.02.24
-6.29%
22.01.24
22.01.24
Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€75.96
02.01.24
02.01.24
€80.00
02.02.24
02.02.24
-6.29%
22.01.24
22.01.24
Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€529.00
18.12.23
18.12.23
€558.00
18.12.24
18.12.24
6.62%
06.01.24
06.01.24
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€526.00
14.12.23
14.12.23
€558.00
14.12.24
14.12.24
0.57%
18.12.23
18.12.23
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Exact Sciences
Start price
Target price
Perf. (%)
€55.41
11.11.23
11.11.23
€105.00
11.12.23
11.12.23
7.56%
25.11.23
25.11.23
Revenue growth >5% per year expected
Rising EBIT margin expected
Standard Investments for future growth
negative Cash Flow expected
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€75.86
04.11.23
04.11.23
€89.00
04.12.23
04.12.23
-4.82%
05.12.23
05.12.23
Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€75.86
04.11.23
04.11.23
€89.00
04.12.23
04.12.23
-4.82%
05.12.23
05.12.23
Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€75.86
04.11.23
04.11.23
€89.00
04.12.23
04.12.23
-4.82%
05.12.23
05.12.23
Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
Sarepta Therapeutics
Start price
Target price
Perf. (%)
€114.20
29.10.23
29.10.23
€150.00
31.03.26
31.03.26
-
30.10.23
30.10.23
Could be very worthwhile Investment >20% year
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€568.50
11.10.23
11.10.23
€558.00
11.10.24
11.10.24
-7.48%
14.12.23
14.12.23
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Amgen Inc.
Start price
Target price
Perf. (%)
€246.80
19.09.23
19.09.23
€250.00
19.09.24
19.09.24
4.13%
27.09.23
27.09.23
Could be worthwhile Investment >10% per year
High dividend yield expected
positive Cash Flow expected
Good rating
Amgen Inc.
Start price
Target price
Perf. (%)
€246.80
19.09.23
19.09.23
€250.00
19.09.24
19.09.24
4.13%
27.09.23
27.09.23
Could be worthwhile Investment >10% per year
High dividend yield expected
positive Cash Flow expected
Good rating
Amgen Inc.
Start price
Target price
Perf. (%)
€246.80
19.09.23
19.09.23
€250.00
19.09.24
19.09.24
4.13%
27.09.23
27.09.23
Could be worthwhile Investment >10% per year
High dividend yield expected
positive Cash Flow expected
Good rating
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€533.50
19.09.23
19.09.23
€558.00
19.09.24
19.09.24
6.56%
11.10.23
11.10.23
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€555.50
15.09.23
15.09.23
€558.00
15.09.24
15.09.24
-3.96%
19.09.23
19.09.23
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market